Breaking News


High expression of insulin-like growth factor binding protein-3 detected in psoriasis


To shed some light onto the functional role of insulin-like growth factor binding protein-3 (IGFBP-3) in psoriasis etiopathogenesis, a clinical trial was set up involving systemic treatment with cyclosporine A or methotrexate and comparison of psoriasis with other inflammatory skin diseases. A total of 30 psoriatic patients were divided in two groups depending on treatment used: group 1 (15 patients) was treated with cyclosporine A and group 2 (15 patients) received methotrexate. A third (17 patients) and fourth (13 patients) group included individuals who exhibited generalized eczema/nummular dermatitis or pitiryasis rosea, respectively, as examples of nonhyperproliferative inflammatory skin diseases. IGFBP-3 expression was significantly higher in biopsies from untreated psoriasis lesions than in biopsies ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list